United States: As ‘Skinny' FDA User Fee Reauthorizations Cross Finish Line, Congress Prepares To Revisit FDA Policy Riders In Lame Duck Session - Akin Gump Strauss Hauer & Feld LLP
On September 30, 2022, Congress enacted legislation to reauthorize the Food and Drug Administration (FDA) user fee programs for branded/reference drugs and biologics...
Full Article